India, March 6 -- Apyx Medical Corporation (APYX) is scheduled to report its financial results for the fourth quarter and fiscal year 2024 before the market opens on Thursday, March 13, 2025.
The company markets its Helium Plasma Platform Technology products - Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It operates in two business segments: OEM and Advanced Energy.
For the fourth quarter of 2024, Apyx Medical expects total revenue to be in the range of $14.1 million to $14.3 million, reflecting a 3% to 4% decrease compared to the total revenue of $12.0 million in the same period in 2023.
Advanced Energy revenue is projected to be approximately $12.0 million to $12.2 million for the fourth quarter...